Premium
Management of the primary cutaneous lymphomas
Author(s) -
Prince H Miles,
McCormack Christopher,
Ryan Gail,
O'Keefe Rod,
Seymour John F,
Baker Chris
Publication year - 2003
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1046/j.1440-0960.2003..x
Subject(s) - medicine , bexarotene , alemtuzumab , immunotoxin , rituximab , cd52 , lymphoma , dermatology , mycosis fungoides , retinoid , chemotherapy , monoclonal , photopheresis , monoclonal antibody , oncology , immunology , antibody , retinoic acid , biochemistry , chemistry , nuclear receptor , transcription factor , gene
SUMMARY Cutaneous lymphomas are rare and, although some are a manifestation of systemic lymphoma, the majority arise primarily from the skin. These primary cutaneous lymphomas comprise both T‐ and B‐cell subtypes and represent a wide spectrum of disorders, which at times can be difficult to diagnose and classify. Classical therapeutic strategies include topical corticosteroids, phototherapy, radiotherapy, retinoids, extracorporeal photopheresis, topical chemotherapy, systemic chemotherapy and biological response modifiers. Newer therapies include the synthetic retinoid bexarotene, the immunotoxin conjugate denileukin diftitox, interleukin‐12 and monoclonal antibodies such as alemtuzumab and rituximab.